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Abstract 
 Background: Ankylosing spondylitis is a chronic inflammatory 
disorder primarily involving the sacroiliac joints and spine. It is associated 
with both articular and extra-articular clinical manifestations, including 
peripheral arthritis, enthesitis, and anterior uveitis.  
Objectives: To compare the serum levels of tumor necrosis factor-like ligand 
1a (TL1A) in ankylosing spondylitis patients and the apparently healthy 
persons; and to find out the association between the cytokine level and 
ankylosing spondylitis disease activity and spinal mobility. 
Patients and Methods: Cross-sectional analytic study conducted in the 
division of rheumatology/Shaheed Hemin general hospital, in Sulymaniyah 
city from (April 2015 to September 2015), on 45 ankylosing spondylitis 
patients with ages ranged between 17 to 52 years. The patients interviewed, 
fully examined, and classified to anti-TNF treated (n=26) and non-biologic 
therapy treated (n=19). Then investigated for the serum levels of TL1A and 
the results were compared with those of 45 age and gender matched 
apparently healthy persons. The cytokine levels also compared with the 
disease activity and spinal mobility parameters. 
Results: The serum levels of TL1A in ankylosing spondylitis patients were 
significantly higher than those of the healthy subjects, with mean and 
standard deviation values of (428.4±285.7 pg./ml), (217.6±64 pg. /ml) 
respectively, the serum levels of TL1A in non-biologics treated ankylosing 
spondylitis patients were significantly higher than those of the healthy 
subjects, with mean and standard deviation values of (576.6±337.4 pg./ml), 
(217.6±64 pg./ml) respectively, and for anti-TNF treated ankylosing 
spondylitis patients mean and standard deviation values of (320.1±181.2 
pg./ml), (217.6±64 pg./ml) respectively, with (P values < 0.001). 
European Scientific Journal November 2015 edition vol.11, No.33 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
198 
Conclusions:  Serum TL1A is up-regulated in ankylosing spondylitis, 
associates with disease activity; and isn’t normalized by anti-TNF therapy, 
suggesting that TL1A may be of pathogenic and potentially of therapeutic 
importance in ankylosing spondylitis. 
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Introduction 
 Ankylosing spondylitis (AS) is a chronic, progressive, inflammatory 
rheumatic disease that primarily affects the sacroiliac joints (Sieper J et al., 
2006). AS is primarily a disease of the axial skeleton, but some patients have 
peripheral joint involvement (Lee JH et al., 2002). AS also has some extra–
articular manifestations (Vander Cruyssen B et al., 2007). The effects of 
environmental factors on genetically susceptible individuals are considered 
to be one possible mechanism for the pathogenesis of AS. It is known to be a 
highly genetic disease and there is a strong genetic association of MHC 
molecules with AS, especially human leukocyte antigen-B27 (HLA-B27) 
(M. F. Shamji et al., 2008).  
 
Epidemiology 
 AS usually initially presents during the third decade of life, and rarely 
after the age of 45 years. The prevalence of AS is generally believed to be 
between 0.1% and 1.4% globally (Akkoc N, 2008). There is some gender 
disparity within AS, with reported gender ratios of around 2:1 (male: 
female), although this estimate has also been shown to vary considerably 
between studies and across time (Braun J and Sieper J, 2007) (Silman AJ and 
Hochberg MC, 2001). 
 
Classification Criteria 
 According to modified New York criteria, a patient can be classified 
as having definite AS if at least one clinical criterion (Inflammatory back 
pain, limitation of lumbar spine or limitation of chest expansion) plus 
radiologic criterion (bilaterally grade 2 or unilateral grade 3-4 sacroiliitis) are 
fulfilled (van der Linden et. al, 1984).  
 
Cytokines in AS 
 Activation of inflammatory cells leads to production of pro-
inflammatory cytokines including TNF-α along with anti-inflammatory 
cytokines. However, an imbalance in favor of pro-inflammatory signals leads 
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to inflammation and subsequently to bone destruction and erosion (van der 
Heijde D et. al, 20081). In contrast to rheumatoid arthritis, repair in AS is 
characterized by new bone formation in the form of syndesmophytes (in 
vertebrae) and enthesophytes (at entheses) (van der Heijde D et al., 20082). 
 
The Tumor Necrosis Factor Superfamily 
 The tumor necrosis factor superfamily (TNFSF) member proteins is a 
group of structurally related cytokines with a wide range of functions in the 
modulation of immunity, inflammation, differentiation, proliferation, and 
programmed death of many different types of cells (Baud V and Karin M, 
2001) (Wajant H et al., 2003). TNFSF, composed of both ligands and 
receptors (TNFRSF), is one of the most successfully and frequently targeted 
protein families with clinical relevance to diverse diseases as cancer, 
autoimmunity, infections, graft rejection, inflammation and osteoporosis 
(Aggarwal BB et al., 2012) (Croft M et al., 2013). TNFSF and TNFRSF are 
critically involved in the pathogenesis of AS (Braun J et al., 1995). 
 While expressions of TNFSF ligands are induced largely on 
professional antigen-presenting cells (APCs; dendritic cells, B cells, 
macrophages), their expression is also reported on T cells, NK cells, mast 
cells, eosinophils, basophils, endothelial cells, thymic epithelial cells, and 
smooth muscle cells (Croft M et al., 2012). 
 
Tumor Necrosis Factor–Like Ligand 1A (TL1A) 
 Tumor necrosis factor–like ligand 1A (TL1A), also called TNFSF15, 
or vascular endothelial growth factor inhibitor (VEGI) is a member of the 
TNFSF. It was identified during homology searches in an endothelial cell 
cDNA library. It is produced by the endothelial cells (T.-S. Migone et al., 
2002), monocytes, dendritic cells (DC), T cells, NKT cells, synovial 
fibroblasts and chondrocytes, either upon stimulation or in situ in 
inflammatory sites (Bamias, G. et al., 2006) (Takedatsu, H. et al., 2008) 
(Zhang, J. et al., 2009) (Prehn, J. L. et al., 2004). Human TL1A consists of 
251 amino acids: 35 in the cytoplasmic domain, 24 in the transmembrane 
region and 192 in the extracellular domain. There are two potential N-linked 
glycosylation sites in the TL1A amino acid sequence, specifically Asparagine 
residues at amino acids 133 and 229 (T.-S. Migone et al., 2002).  
 In contrast to the TNF-α receptors, which are expressed on essentially 
all cells, the receptor for TL1A, death receptor 3 (DR3), is primarily 
expressed on T cells, natural killer (NK) cells, and NK T (NKT) cells, 
thereby limiting the effects of TL1A (T.-S. Migone et al., 2002) (Meylan, F. 
et al., 2008). In recent years, the DR-3/TL1A axis has emerged as a key 
regulator of inflammation and autoimmunity in its own right, with in vivo 
studies of transgenic mice deficient for DR-3 or TL1A and those 
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overexpressing TL1A or dominant-negative forms of DR-3 providing 
compelling evidence for an essential role of the DR-3/ TL1A axis in many 
models of inflammatory and autoimmune disease (Bamias, G. et al., 2006) 
(Calder CJ and Wang EC, 2012). 
 Like other members of the TNFSF, TL1A enhances T cell 
proliferation and cytokine production of T cells activated in vitro. 
Proliferation is particularly enhanced in cells sub-optimally activated in the 
absence of CD28, and this effect is more pronounced in memory vs. naïve T 
cells, perhaps because of greater expression of the full-length isoform of 
DR3 in memory T cells (Bamias, G. et al., 2006) (Meylan, F. et al., 2008). 
 TL1A-associated pathways represent targets of potential therapeutic 
importance, as they are implicated in the pathogenesis of several 
inflammatory diseases, including inflammatory bowel disease (Bamias, G. et 
al., 2006), atherosclerosis (Kang YJ et al., 2005) and rheumatoid arthritis 
(Borysenko CW et al., 2005). Also, identification of a link between the 
DR3/TL1A pathway and the spondyloarthritides was first demonstrated 
when single-nucleotide polymorphisms (SNPs) located in the direct vicinity 
of the TNFSF15 gene were shown to be strongly associated with 
predisposition to spondylo-arthropathies including AS (E. Zinovieva et al., 
2009). 
 
Current Therapies and Future Novel Therapies 
 Non-steroidal anti-inflammatory drugs (NSAIDs), including selective 
cyclo-oxygenase 2 inhibitors, are the recommended first-line 
pharmacological therapy for AS, but many patients achieve insufficient 
symptom control with NSAIDs alone. Conventional disease-modifying 
antirheumatic drugs (DMARDs) are of limited use. Sulfasalazine and 
methotrexate are not effective for the treatment of patients with axial disease. 
(Braun J et al., 2010). TNF antagonists (etanercept, infliximab, golimumab 
and adalimumab) have demonstrated clinical efficacy in short-term and long-
term clinical trials (Désirée van der Heijde et al., 2015). But, for some 
patients, the initial response to anti-TNF-α agents diminishes over time and 
they are switched to another anti-TNF agent (Haberhauer G et al., 2010). 
However, if TNF-blockade fails to control AS disease activity, no other 
treatment options are currently available (Rajalingham S and Das S., 2012). 
 
Bath Ankylosing Spondylitis Metrology Index (BASMI) 
 The BASMI is included in the Assessment of SpondyloArthritis 
international Society (ASAS) core sets as the preferred measure of spinal 
mobility. It has been used in clinical trials of anti–tumor necrosis factor 
agents in AS patients (Brandt J et al., 2003) (Brandt J et al., 2000), and more 
recently was the outcome measure used to show that spinal mobility is 
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determined by both spinal inflammation and by structural damage (Machado 
P et al., 2010). 
 
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
 BASDAI is a score used to measure patient-reported disease activity 
in patients with ankylosing spondylitis. The instrument was first published in 
1994 using visual analog scales (Garrett S et al., 1994). The BASDAI has 
been endorsed by the Assessment of SpondyloArthritis international Society 
(ASAS) for the measurement of disease activity (Zochling J et al., 2008). 
The BASDAI has been the most frequently used measure of disease activity 
in clinical trials (Brandt J et al., 2000), and is recommended to assess 
response to anti–tumor necrosis factor therapies in AS patients (Braun J et 
al., 2003). 
 
Patients and Methods 
 Forty five AS patients enrolled in this cross-sectional analytic study, 
which had been diagnosed according to the Modified New York criteria, 
which include the followings:  
1. Radiological criterion: 
• Sacroiliitis at least grade 2 bilaterally or grade 3 or 4 unilaterally. 
2. Clinical criteria: 
• Low back pain and stiffness for more than 3 months that improves 
with exercise but is not relieved by rest. 
• Limitation of motion of the lumbar spine in both the sagittal and 
frontal planes. 
• Limitation of chest expansion relative to normal values correlated for 
age and gender. 
 A definite diagnosis of ankylosing spondylitis requires the 
radiological criterion and at least one clinical criterion. 
 The AS patients were recruited from the department of rheumatology 
in Shaheed Dr. Hemin general teaching hospital and the center of 
rheumatology and rehabilitation in Sulaymaniyah city. Forty five apparently 
healthy control subjects were selected among paramedical personnel and 
apparently healthy blood donors (age and gender matched with the AS 
patients) at Sulaymaniyah central blood bank, after obtaining their informed 
consent. 
 Both AS patients and normal controls were recruited in the period 
from April 2015 to September 2015. The normal controls were interviewed; 
general information recorded, past medical and drug history taken, physical 
examination and laboratory investigations done (including complete blood 
count and viral screen). 
 A protocol was designed for all AS cases to record age, gender, 
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address, occupation, duration of illness, drug history, BASDAI, BASMI. 
Verbal informed consent was taken from all cases. A proper history and 
physical examination were undertaken and all clinical and laboratory 
parameters involved in BASMI and BASDAI were measured.  
 The blood samples were taken from both AS patients and healthy 
controls for the estimation of the serum levels of TL1A. Then, the levels of 
the cytokine were compared to BASDAI and BASMI scores of each patient. 
 Disease activity of AS patients was assessed through Bath 
Ankylosing Spondylitis Disease Activity Index (BASDAI), and spinal 
mobility was measured through Bath Ankylosing Spondylitis Metrology 
Index (BASMI). 
 The Human TL1A ELISA kit was a quantitative assay kit for 
detection of human TL1A in serum, plasma and biologic fluids using a 
(Sandwich Immunoassay Technique). The TL1A ELISA kit was from 
(MyBioSource). The detection range of the cytokine in the serum is (78-2500 
pg/ml), and it’s used for research purposes only (not for diagnostic 
purposes). 
 
Statistical Analysis 
 All patients' data entered using computerized statistical software; 
Statistical Package for Social Sciences (SPSS) version 17 was used. 
Descriptive statistics presented as (mean ± standard deviation) and 
frequencies as percentages. Kolmogorov Smirnov analysis verified the 
normality of the data set. Multiple contingency tables conducted and 
appropriate statistical tests performed, t-test was used to compare between 
two means. One way ANOVA analysis was used to compare between more 
than two means. Pearson Correlation test was used to assess relationship 
between continuous variables. In all statistical analysis, level of significance 
(p value) set at ≤ 0.05 and the result presented as tables and/or graphs. 
 
Results 
Demographic Data 
 A total of 45 ankylosing spondylitis (AS) patients were included in 
this study with mean age of 33.6±3.8 years. Male AS patients were more 
than females with male to female ratio as 2.7:1. 
 Mean AS duration of studied patients was 7.6±7.3 years, 44.4% of 
them had AS duration more than 5 years. 
 Mean age of controls was 33.6±8.8 years, Males were more than 
females. 
 No significant differences were observed between AS patients and 
controls regarding gender (p=0.3), and age (p=0.07). 
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Table 1: Demographic Characteristics of AS Patients and Controls 
Variable  AS Control  χ² P  
No. % No. % 
Age 8.4* 0.07 
< 20 years 3 6.7 1 2.2 
20-29 years 13 28.9 11 24.4 
30-39 years 17 37.8 29 64.4 
40-49 years 10 22.2 3 6.7 
≥ 50 years 2 4.4 1 2.2 
Gender  0.8 0.3 
Male  33 73.3 29 64.4 
Female  12 26.7 16 35.6 
 
Clinical Data 
 Enthesitis was present among 57.8% of AS patients and peripheral 
arthritis was present among 42.2% of them. 
Table 2: Clinical Findings of AS Patients 
Variable No. % 
Enthesitis 
Present 26 57.8 
Absent 19 42.2 
Total 45 100.0 
Peripheral arthritis 
Present 19 42.2 
Absent 26 57.8 
Total 45 100.0 
 
AS Patients According to Treatment Methods 
 More than half (57.8%) of AS patients were on anti-TNF therapy and 
42.2% of them were on non-biologic therapy. 
Figure 1: AS Patients According to Pharmacologic Therapy 
 
 
57.8% 
42.2% 
anti-TNF therapy
Non-biologic therapy
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Laboratory Findings  
 A significant association was observed between TL1A titer and AS 
(p<0.001).  
Table 3:  TL1A Titers in AS Patients and Controls 
Variable AS Control t-test P 
Mean±SD Mean±SD 
TL1A titer 428.4±285.7 217.6±64 4.8 <0.001 
 
Figure 2: TL1A Titers in AS Patients and Controls 
 
 
 There were highly significant differences between serum TL1A levels 
of non-biologic treated AS cases and controls (p< 0.001). 
 There were highly significant differences between serum TL1A levels 
of anti-TNF treated AS cases and controls (p< 0.001). 
 There were highly significant differences between serum TL1A levels 
of anti-TNF treated AS cases and AS cases on non-biologic therapy (p< 
0.002). 
Table 4: TL1A Titers in the Three Groups 
Study Groups TL1A 
Mean±SD 
AS cases on anti-TNF therapy 320.1±181.2 
AS cases on non-biologic therapy 576.6±337.4 
Controls 217.6±64 
ANOVA (P value) <0.001 
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Figure 3: TL1A Titers in the Three Groups 
 
 
Figure 4: TL1A titers of AS Patients on anti-TNF and Controls 
 
 
BASDAI and BASMI Scores of the Patients 
 Mean BASDAI scores of AS patients were 3.8±1.3, 44.4% of AS 
patients were active according to BASDAI scores. Mean BASMI scores of 
AS patients were 3.7±1.9. 
 A significant association was observed between active AS patients 
(BASDAI score≥4) and TL1A titer (p=0.001). 
 There was no significant association between the BASMI scores of 
the AS patients and their TL1A titers (p=0.1). 
Table 5: TL1A Titers of the Active and Inactive AS Patients (BASDAI) 
Variable Inactive AS Active AS t-test P 
Mean±SD Mean±SD 
TL1A titer 304.2±182.5 583.7±318.3 3.7 0.001 
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Figure 5: TL1A Titers of the Active and Inactive AS Patients (BASDAI) 
 
 
Discussion 
 Ankylosing spondylitis (AS), a prototype of seronegative 
spondyloarthropathies, is a chronic inflammatory disease mainly affecting 
the axial skeleton. In addition to an HLA-B27 association (Marcilla M and 
López de Castro JA, 2008) (López de Castro JA, 2007), the pathogenesis of 
AS may involve a preceding infection (Kim TH, 2005) and an abnormal 
cytokine expression (Cañete JD, 2000). A number of studies that examined 
cytokine levels in AS have shown varied results. There seemed to have a 
general trend toward raised serum pro-inflammatory cytokine levels. 
However, serum anti-inflammatory cytokines such as IL-10 were also 
demonstrated to be increased in AS patients. Besides, both CD4+ and CD8+ 
T cells are considered to participate in the inflammatory processes of AS 
(Cañete JD, 2000) (Schirmer M, 2002). Among pro-inflammatory cytokines 
in AS, TNFSF and TNFRSF members are critically involved (Braun J et al., 
1995). 
 Thirty three (73.3%) of our patients were males while twelve (26.7%) 
were females, with a female to male ratio of (2.7:1), which was close to the 
ratio of (Lee W et al., 2007) and (Boonen A et al., 2003); who reported male 
to female  ratio of (2-3 : 1) among AS patients. 
 The mean of the ages of AS patients was (33.6±3.8) years, which was 
close to that of (Feldtkeller E et al., 2003), who found in a survey of 1080 AS 
patients that the age at diagnosis of HLA-B27 positive and negative patients 
was 39.1 and 33.2 years, respectively. 
 Peripheral arthritis was present in 42.2% of AS patients. This result 
was close to what was mentioned by (Tae-Jong Kim et al., 2014); who found 
that peripheral arthritis occurs in 30-40% of AS patients across the course of 
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their disease, but lower than what (Ji-Hyun Lee et al., 2002) concluded, who 
found that among 257 cases of adult AS, 61% of them had peripheral 
arthritis. 
 Among our cases, 26 of them (57.8 %) had enthesitis. This result was 
near to what was obtained by (Spadaro A et al., 2011); who found enthesitis 
through clinical examination in 63.3% of 36 AS cases, although he found a 
higher number of enthesitis when he examined the cases by ultrasonography. 
 A significant association was observed between TL1A titer and AS 
(p<0.001). This association remained significant even in patients treated with 
biological anti-TNF therapy. 
 There was a significant association between AS cases on non-
biologic therapy and TL1A titer (p<0.001). This result was close to that of 
(Maria Konsta et al., 2013); who referred also to highly significant difference 
(P = 0.042). 
 Although the serum level of TL1A was affected by anti-TNF therapy 
(576.6±337.4 in non-biologic treated vs. 320.1±181.2 in anti-TNF treated) 
there was a significant difference between serum TL1A levels of anti-TNF 
treated AS cases and controls (p< 0.001). 
 The level of serum TL1A remained significantly different between 
AS cases treated with non-biologic therapy and those treated with biologic 
anti-TNF therapy (p value 0.002). 
 Convincing evidence from several short term randomized controlled 
trials indicates that treatment of AS with anti-TNF agents is safe and 
efficacious (Braun J et al., 2002) (Gorman JD et al., 2002) (Van Den Bosch F 
et al., 2002). However, as (Baeten D et al., 2001) and (Zou JX et al., 2003) 
noted, a subset of patients fails to respond or does not sustain initial 
responses. As for our study, 11 of our anti-TNF treated cases (42.3%) have 
active disease according to BASDAI scores. 
 Inefficacy of anti-TNF therapy in some cases was observed by many 
researchers; like (Suzanne Arends et al., 2011), which followed up 220 AS 
cases on anti-TNF therapy and assessed their response to the therapy. At 
three and six months, 68% and 63% of patients were Assessments in 
Ankylosing Spondylitis (ASAS)20 responders, 49% and 46% ASAS40 
responders, and 49% and 50% Bath Ankylosing Spondylitis Disease Activity 
Index (BASDAI)50 responders, respectively. 
 In one study; (Braun J and Sieper J, 2007) found that 30–40% of 
patients experience substantial disease activity despite anti-tumour necrosis 
factor therapy. 
 Other researchers; like (Kavanaugh A et al., 2006) concluded that 
although anti-TNF-α have a dramatic effect on the treatment of 
spondyloarthritis, almost 30% of the patients will have to discontinue their 
treatment prematurely due to loss of efficacy or side effects. These 
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observations drew the attention that there may be other inflammatory 
pathways different from TNF-α pathway, included in the pathogenesis of AS, 
and this is evident from cases having active disease despite anti-TNF 
therapy. 
 In another study; (S Jin et al., 2013) investigated the mechanism of 
TL1A induced inflammation in human CD4+ T cells and compared the 
effects to the TNF-α induced pathway. They concluded that both soluble and 
membrane TL1A directly induces pro-inflammatory cytokines from CD4+ 
CD161+ T cells, while these cells are resistant to TNF-α. More importantly, 
they discovered that TL1A induces TNF-α expression from CD161+ T cells, 
suggesting that TL1A is upstream of TNF-α. Soluble and membrane TL1A-
induced cytokine expression was inhibited by a novel neutralizing anti-TL1A 
antibody, but not by an anti-TNF-α antibody, indicating that TL1A directly 
affects CD161+ T cells. Notably (Tae-Hwan Kim et al., 2005) and (Paul 
Bowness et al., 2011) concluded that, CD4+ T cells are involved in the 
pathogenesis of AS, and as (S Jin et al., 2013) concluded; CD161 (also 
known as KLRB1) is expressed on approximately 25% of their blood-
resident CD4+ T cells. Others like (T.-S. Migone et al., 2002) also found that 
while IL-2, IFN-γ, and CD25 were all predicted as responsive to TL1A, they 
were surprised to see that TL1A induced TNF-α from CD4+ T cells. 
 Finding a biomarker for diagnosis of AS is eagerly needed, as in the 
context of all the inflammatory rheumatic diseases, there is an unacceptably 
long delay between the onset of symptoms and the time of diagnosis for AS 
—an average interval of 8–11 years has been reported (Feldtkeller E et al., 
2003).  Early diagnosis and treatment of AS is important because it can 
reduce the disease disability (McLeod C et al., 2007). 
 In this study; there was a significant association between active AS 
patients (BASDAI score≥4) and TL1A titer (p=0.001), which is comparable 
to the results of (Maria Konsta et al., 2013); who  observed a positive 
correlation between individual levels of TL1A and BASDAI (P = 0.008). 
 Having a biomarker to show AS disease activity is crucial, because, 
in contrast to rheumatoid arthritis, where ESR and CRP correlate well with 
disease activity, laboratory biomarkers that correlate with disease activity in 
AS has proved to be elusive. Studies assessing the role of ESR and CRP in 
AS, suggested that they correlated poorly with disease activity (Pathan, Ejaz 
Mohammed Ishaq, 2013). 
 No significant association were observed between AS patients’ 
BASMI scores and TL1A titers (p=0.1), this was close to the results 
concluded by (Maria Konsta et al., 2013) who found that there were no 
significant association between TL1A level and AS Metrology parameters 
namely (Schober test, Occiput to wall distance, Cervical rotation, Cervical 
flexion and Lateral spinal flexion) with P values (0.87, 0.57, 0.7, 0.9 and 0.9) 
European Scientific Journal November 2015 edition vol.11, No.33 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
209 
respectively. 
 
Conclusions 
 Serum TL1A is up-regulated in ankylosing spondylitis, associates 
with disease activity which could be used as a useful tool in the follow up of 
AS patients, and isn’t normalized by anti-TNF therapy; suggesting that TL1A 
may be of pathogenic and potentially of therapeutic importance in 
ankylosing spondylitis in the future (new novel therapies), apart from TNF-
blockade. 
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